CoronavirusDrug SafetyOpioids

Testing lab challenges FDA findings that carcinogens in metformin do not exceed acceptable levels

As questions about suspected carcinogens in drugs continue to roil the supply chain, the FDA last month said its testing of metformin did not find any with unacceptably high levels of NDMA. But testing laboratory Valisure has challenged those findings in a new Public Citizen petition, saying it discovered problems in 42% of the batches it checked. It contends the situation is likely to get worse as the COVID-19 outbreaks wreak havoc on supply chains.

Read the source article at Pharma News

    Leave a Review or Comment

    Your email address will not be published.

    Back to top button